Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
-
Le Tourneau, C. (Paris-Saclay University)
;
Becker, H. (University of Freiburg) ;
Claus, R. (Medical Faculty Augsburg University) ;
Elez, Elena (Vall d'Hebron Institut d'Oncologia) ;
Ricci, F. (Paris-Saclay University) ;
Fritsch, R. (University of Freiburg) ;
Silber, Y. (Medical Faculty Augsburg University) ;
Hennequin, A. (Centre Georges-François Leclerc) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Jayadeva, G. (Boehringer Ingelheim International GmbH) ;
Luedtke, D. (Boehringer Ingelheim Pharma GmbH and Co KG) ;
He, M. (Boehringer Ingelheim Pharmaceuticals Inc.) ;
Isambert, N. (Centre Georges-François Leclerc) ;
Universitat Autònoma de Barcelona
visitant ::
identificació
Subscriure's to this discussion. You will then receive all new comments by email.
